Latest R. Scott Turner Stories
In the future, your optometrist may be the first person to realize that you could have Alzheimer’s disease. An international team of researchers has discovered the loss of a particular layer of retinal cells may reveal the presence of the disease.
When Georgetown University neurologist R. Scott Turner, MD, PhD, began enrolling people with mild to moderate Alzheimer's disease into a nationwide study last year, he expected to find only a handful of participants with undiagnosed glucose intolerance, as all the patients were already under a doctor's care and those with known diabetes were excluded.
A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months.
Patients with Alzheimer's disease who are in the early stages of their illness will likely benefit most from vaccine therapies now being tested in a number of human clinical trials.
Researchers in the Memory Disorders Program at Georgetown University Medical Center are now recruiting volunteers for a national gene therapy trial â€“ the first study of its kind for the treatment of patients with dementia due to Alzheimer's disease.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.